Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer
Roslin Y. Docta, Tiago Ferronha, Joseph P. Sanderson, Thomas Weissensteiner, George R. Pope, Alan D. Bennett, Nicholas J. Pumphrey, Zoltan Ferjentsik, Laura L. Quinn, Guy E. Wiedermann, Victoria E. Anderson, Manoj Saini, Miguel Maroto, Elliot Norry, Andrew B. Gerry – 18 December 2018 – Patients with hepatocellular carcinoma (HCC) have a poor prognosis and limited therapeutic options. Alpha‐fetoprotein (AFP) is often expressed at high levels in HCC and is an established clinical biomarker of the disease.